We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current LXRX market cap is 232.08M. The company's latest EPS is USD -0.4900 and P/E is -1.45.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 162k | 702k | 1.13M | 1.65M | 1.75M |
| Operating Income | -49.63M | -46.74M | -45.33M | -55.35M | -63.69M |
| Net Income | -50.53M | -49.76M | -48.4M | -53.43M | -64.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 322.07M | 24M | 298k | 139k | 1.2M |
| Operating Income | 141.45M | -180.39M | -87.09M | -100.76M | -171.75M |
| Net Income | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 276.48M | 229.43M | 417.22M | 373.36M | 321.12M |
| Total Liabilities | 136.97M | 136.32M | 128.35M | 133.38M | 142.61M |
| Total Equity | 139.51M | 93.11M | 288.87M | 239.98M | 178.51M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 417.72M | 203.79M | 136.91M | 194.3M | 229.43M |
| Total Liabilities | 300.61M | 47.42M | 23.31M | 77.18M | 136.32M |
| Total Equity | 117.1M | 156.37M | 113.6M | 117.12M | 93.11M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -111.35M | -161.9M | -55.13M | -103.67M | -157.29M |
| Investing | -101.84M | -49.94M | -110.22M | -122.55M | -69.08M |
| Financing | 187.96M | 187.96M | 239.38M | 239.37M | 238.45M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 113.81M | -142.97M | -87.02M | -88.85M | -161.9M |
| Investing | -155.86M | 380.76M | 2.11M | -71.08M | -49.94M |
| Financing | -2.23M | -147.64M | 22.71M | 142.21M | 187.96M |
| Market Cap | 232.08M |
| Price to Earnings Ratio | -1.45 |
| Price to Sales Ratio | 215.15 |
| Price to Cash Ratio | 11.43 |
| Price to Book Ratio | 2.76 |
| Dividend Yield | - |
| Shares Outstanding | 361.49M |
| Average Volume (1 week) | 6.4M |
| Average Volume (1 Month) | 5.14M |
| 52 Week Change | -48.64% |
| 52 Week High | 3.73 |
| 52 Week Low | 0.61 |
| Spread (Intraday) | 0.08 (10.99%) |
| Company Name | Lexicon Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.lexpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
